• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Perspective Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    5/1/25 5:05:55 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care
    Get the next $CATX alert in real time by email
    8-K
    false000072838700007283872025-05-012025-05-01

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 01, 2025

     

     

    Perspective Therapeutics, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-33407

    41-1458152

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    c/o Perspective Therapeutics, Inc.

    2401 Elliott Avenue

    Suite 320

     

    Seattle, Washington

     

    98121

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (206) 676-0900

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.001 par value

     

    CATX

     

    NYSE American LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 8.01 Other Events.

    On May 1, 2025, Perspective Therapeutics, Inc. updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit No.

     

    Description

    99.1

     

    Corporate Presentation.

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    PERSPECTIVE THERAPEUTICS, INC.

     

     

     

     

    Date:

    May 1, 2025

    By:

    /s/ Juan Graham

     

     

     

    Juan Graham, Chief Financial Officer

     


    Get the next $CATX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CATX

    DatePrice TargetRatingAnalyst
    3/13/2025$10.00Buy
    H.C. Wainwright
    3/7/2025$15.00Sector Outperform
    Scotiabank
    11/25/2024$24.00 → $5.00Buy → Neutral
    BofA Securities
    10/24/2024$20.00Buy
    UBS
    10/1/2024$25.00Outperform
    Wedbush
    9/25/2024$21.00Buy
    Truist
    7/25/2024$24.00Buy
    BofA Securities
    5/9/2024Overweight
    Cantor Fitzgerald
    More analyst ratings

    $CATX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Spoor Johan M. bought $59,673 worth of shares (26,676 units at $2.24), increasing direct ownership by 59% to 59,383 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 6:44:41 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Director Williamson Robert F Iii bought $132,151 worth of shares (60,337 units at $2.19), increasing direct ownership by 124% to 108,982 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 5:04:49 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Graham Juan bought $74,946 worth of shares (33,333 units at $2.25), increasing direct ownership by 1,649% to 35,354 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 5:03:59 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Spoor Johan M. bought $59,673 worth of shares (26,676 units at $2.24), increasing direct ownership by 59% to 59,383 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 6:44:41 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Director Williamson Robert F Iii bought $132,151 worth of shares (60,337 units at $2.19), increasing direct ownership by 124% to 108,982 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 5:04:49 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Graham Juan bought $74,946 worth of shares (33,333 units at $2.25), increasing direct ownership by 1,649% to 35,354 units (SEC Form 4)

      4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

      4/1/25 5:03:59 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    SEC Filings

    See more

    $CATX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form 10-Q filed by Perspective Therapeutics Inc.

      10-Q - Perspective Therapeutics, Inc. (0000728387) (Filer)

      5/12/25 4:34:55 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

      5/12/25 4:30:53 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

      5/1/25 5:05:55 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • H.C. Wainwright initiated coverage on Perspective Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $10.00

      3/13/25 7:26:51 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Scotiabank initiated coverage on Perspective Therapeutics with a new price target

      Scotiabank initiated coverage of Perspective Therapeutics with a rating of Sector Outperform and set a new price target of $15.00

      3/7/25 8:03:16 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Perspective Therapeutics from Buy to Neutral and set a new price target of $5.00 from $24.00 previously

      11/25/24 7:39:30 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

      First of several clinical updates through mid-2026 accepted for presentation at the 2025 American Society of Clinical Oncology Annual Meeting, with recruitment progressing for all three of our clinical stage potential new medicines based on our next generation targeted radiopharmaceutical technology platformEnrollment ongoing for VMT-α-NET, a next generation SSTR2-targeting potential new medicine, with 40 patients enrolled through end of April 2025 in Cohort 2 of the Phase 1/2a trial in neuroendocrine tumorsEnrollment ongoing for VMT01, a first-in-class MC1R targeting potential new medicine, with first patient treated at a new monotherapy dose level in April 2025, following the first patient

      5/12/25 4:36:46 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics to Participate in Upcoming May Investor Conferences

      SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate and be available for one-on-one meetings with investors at the following upcoming investor conferences. Bank of America Global Healthcare ConferenceDate: Tuesday, May 13, 2025Format: Fireside ChatTime: 11:35 a.m. – 11:50 a.m. PT / 2:35 p.m. – 2:50 p.m. ETLocation: Las Vegas, NV 2025 RBC Capital Markets Global Healthcare Conference Date: Tuesday, May 20, 2025Format: Fireside ChatTime: 3:05 p.m. - 3:30 p.m

      5/1/25 7:00:00 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors

      SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced today that the first patient was treated with [212Pb]PSV359 in a Phase 1/2a dose-finding trial to determine safety and preliminary anti-tumor activity of the radiopharmaceutical [212Pb]PSV359 in patients with solid tumors that express fibroblast activation protein alpha (FAP-α). Patients are being selected for [212Pb]PSV359 targeted alpha particle therapy by SPECT imaging with [203Pb]PSV359. "We are excited to explore a new avenue to treat cancers expressing FAP-α wi

      4/29/25 7:00:00 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Perspective Therapeutics Inc.

      SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

      11/14/24 6:14:40 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Perspective Therapeutics Inc.

      SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)

      11/14/24 4:05:13 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Perspective Therapeutics Inc.

      SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)

      11/7/24 9:24:55 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    Leadership Updates

    Live Leadership Updates

    See more
    • Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

      SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the appointment of Juan Graham as the Company's Chief Financial Officer (CFO), effective as of January 6, 2025. In connection with the transition, Jonathan Hunt will no longer serve as CFO but will continue serving as the Company's Chief Accounting Officer (CAO). "In less than 18 months, Perspective has delivered initial clinical data for two new potential medicines based on its next generation targeted radiopharmaceutical technology platform,

      1/6/25 8:00:00 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics Announces Inclusion in the Russell 3000® Index

      SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to an updated list of additions to the membership list, considered to be final, as of Monday, June 10th. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total mark

      6/12/24 7:00:00 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights

      Phase I/2a clinical trials initiated: VMT-α-NET for neuroendocrine tumors, and VMT01 for melanoma. Preliminary results from initial cohorts expected by end of 2023.First patient dosed in Phase 1/2a dose escalation trial of VMT01 for treatment of MC1R-positive metastatic melanoma. RICHLAND, Wash. and CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, reports second quarter financial results for the period end

      8/11/23 8:00:30 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care

    $CATX
    Financials

    Live finance-specific insights

    See more
    • Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

        Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding for [212Pb]VMT-α-NET[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested Three of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. First responses for two patients occurred after end of treatment period and are subject to confirmation, in addition to the previously reported patient with confirmed response who remains in response The five other patients in Coh

      1/24/25 7:00:00 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025

      SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that an abstract on updated interim results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET (NCT05636618) has been accepted as a poster presentation at the ASCO Gastrointestinal Cancers Symposium (ASCO-GI) taking place on January 23-25, 2025 in San Francisco, CA. The poster presentation entitled "Interim Safety and Efficacy data of [212Pb]VMT-α-NET in Somatostatin Receptor 2 (SSTR2) Expressing Neuroendocrine Tumors (NETs)" will

      1/22/25 7:00:00 AM ET
      $CATX
      Medical/Dental Instruments
      Health Care
    • Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

      SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium taking place November 21-23, 2024 in Chicago. The presentation entitled "Preliminary safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs)" will be p

      11/15/24 4:08:05 PM ET
      $CATX
      Medical/Dental Instruments
      Health Care